High-dose atorvastatin reduced PAD incidence in post-MI patients

In patients with previous MI, therapy with high-dose atorvastatin significantly decreased the incidence of peripheral arterial disease compared with moderate-dose simvastatin, according to data from the American Heart Association. Further, patients with a history of PAD at baseline had greater risk for future CV events, but this risk was lowered with high-dose atorvastatin. Researchers believe that high-risk patients, including patients with PAD, should be initially treated with high-intensity statin therapy.